Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05212384 plus irinotecan versus cetuximab plus irinotecan in KRAS/NRAS wild-type metastatic colorectal cancer
2013-002095-40Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gedatolisib, irinotecan and cetuximab in colorectal cancer (CRC) (3 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Feb 2014; status: completed.
02
Drugs
gedatolisibirinotecancetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2013-002095-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002095-40.